SecBot SecBot
SECBOTREPLAY Home › Report › CRVS

CRVS · Corvus Pharmaceuticals reported financial results for Q4 and full year…

Corvus Pharmaceuticals, Inc. · PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET

Corvus Pharmaceuticals reported financial results for Q4 and full year 2025, highlighted by positive Phase 1 atopic dermatitis trial data for soquelitinib, initiation of a Phase 2 trial in the same indication, and a successful $189 million public offering extending cash runway into Q2 2028. Despite increased R&D spending and a slight YoY increase in net loss, the company is advancing multiple clinical programs with upcoming data catalysts.

  • Positive Phase 1 data in atopic dermatitis: 75% of soquelitinib patients achieved EASI 75 vs. 20% placebo; no severe adverse events.
  • Initiated Phase 2 atopic dermatitis trial with ~200 patients; additional Phase 2 trials in asthma and hidradenitis suppurativa planned for 2026.
  • Completed public offering raising $189.4 million in net proceeds, extending cash runway into Q2 2028.
  • Cash, cash equivalents, and marketable securities: $56.8 million as of December 31, 2025 (excluding $189.4 million from January 2026 financing).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access